Scientific investigations sometimes result in serendipitous discoveries which shift the investigations from one focus to another. In the case of researchers at Mayo Clinic in Arizona, studies addressing obesity’s impact on cancer treatment resulted in an unexpected discovery that shifted the focus from cancer to obesity. The investigators observed that two common cancer-fighting drugs sparked significant weight loss in the obese mice, even though the mice continued their excessive consumption of a high-fat diet.
These results, which are part of a Mayo Clinic study, were reported in the Jan. 17 edition of Oncotarget.
“We were surprised to observe that when morbidly obese mice were treated with certain cancer-fighting drugs, the drugs not only targeted their cancers, but also tended to spontaneously resolve their obesity ? even with undiminished gorging on a high-fat diet,” says Mayo Clinic cancer immunotherapist Peter Cohen, M.D., who co-led the study with postdoctoral fellow Cheryl Myers, Ph.D. and Mayo Clinic immunologist Sandra Gendler, Ph.D.
“Importantly, two chemotherapy agents ? methotrexate and cyclophosphamide ? could be dosed to completely reverse obesity without detectable toxicity, even in mice without cancer,” explains Dr. Myers. “Interestingly, these drugs are already used to treat some noncancerous conditions, such as rheumatoid arthritis.”
More research needs to be done to see if the same outcome can be achieved in morbidly obese patients.
“The ease with which this weight loss was achieved in mice ? even with continued caloric binging ? is in stark contrast to the Herculean difficulties morbidly obese patients experience trying to preserve weight loss through dietary restraint,” adds Dr. Gendler.
The weight reduction observed in the obese mice was not attributable to trivial explanations, such as a decrease in dietary intake, increased energy expenditure or malabsorption. Instead, the investigators identified multiple effects of methotrexate or cyclophosphamide that worked together to expedite loss of excessive weight in mice. Much like chemotherapy’s well-known ability to decrease red and white blood cell precursors transiently, methotrexate or cyclophosphamide depleted fat cell precursors, leading to much decreased fat storage. “This meant that excessive dietary calories had to go somewhere else in the body instead, such as to the liver,” explains Dr. Cohen.
“Surprisingly, the liver maintained a robust level of metabolic activity during methotrexate or cyclophosphamide treatment, but was nearly shut down in regards to fat production and fat storage,” adds Dr. Myers.
“Based on our composite data,” explains Dr. Gendler, “it appears that methotrexate or cyclophosphamide can induce the livers of obese mice to burn off rather than accumulate excessive dietary fat. This results in desirable weight reduction instead of increased obesity, even with continued caloric binging.”
The study sets the stage for further research, exploring how these metabolic mechanisms could reduce the need for severe dietary constraints in morbidly obese individuals.
[osd_subscribe categories=’weight loss’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “WEIGHT LOSS”‘]
Receive an email update when we add a new WEIGHT LOSS article.
The Latest on: Methotrexate and cyclophosphamide
via Google News
The Latest on: Methotrexate and cyclophosphamide
- Methotrexate, which can end a pregnancy, is also used to treat certain diseaseson July 28, 2022 at 9:02 am
Medical organizations are reporting that some patients can’t access methotrexate in states with abortion bans. The drug is used to treat serious health conditions.
- Treatments for Gestational Trophoblastic Diseaseon July 27, 2022 at 5:00 pm
CO: Cyclophosphamide and vincristine; EMA: Etoposide, methotrexate and actinomycin D; iv.: Intravenous. 1 Paclitaxel 135 mg/m 2 by iv. infusion over 3 h Cisplatin 60 mg/m 2 iv. infusion over 3 h ...
- Low-Intensity Therapy in Adults with Burkitt's Lymphomaon July 20, 2022 at 5:00 pm
The median cumulative doses of doxorubicin–etoposide and cyclophosphamide administered ... involvement received prophylactic intrathecal methotrexate at a dose of 12 mg. Intrathecal treatment ...
- Intravitreal Methotrexate Reduces Reoperation After Retinal Detachment Repairon July 18, 2022 at 1:32 pm
Postoperative intravitreal methotrexate for retinal detachment led to a significant reduction in reoperation and improved visual acuity, a retrospective chart review showed. The absolute difference in ...
- Arthritis Patients Are Being Denied Methotrexate Post-Dobbs. Are People With Cancer Next?on July 18, 2022 at 5:39 am
Methotrexate is an important therapy for cancer and some oncologists are concerned about the potential knock-on effect of the supreme court decision on patients.
- How overturning Roe V. Wade is affecting access to autoimmune medicationson July 7, 2022 at 5:00 pm
some individuals with these conditions respond better to methotrexate and other teratogenic drugs such as mycophenolate and cyclophosphamide. The disruption of access to methotrexate and other ...
- A trial looking at treatment for children and young adults with an ependymoma (SIOP Ependymoma Program II) Pathway 2on July 4, 2022 at 5:00 pm
cyclophosphamide and high dose methotrexate After this a small amount of tumour might remain. Where possible you have further surgery to remove it. Where this isn’t possible giving 2 more doses of ...
- ICCG FEC Trialon June 24, 2022 at 3:22 pm
A randomised trial comparing cyclophosphamide, methotrexate & 5-fluorouracil (CMF) with 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in patients with node negative primary breast cancer. A ...
- Which maintenance therapy for ANCA vasculitis?on March 5, 2019 at 2:46 am
the French Vasculitis Study Group compared the use of methotrexate and azathioprine for maintenance therapy of ANCA-associated vasculitis after induction of remission with cyclophosphamide and ...
via Bing News